Description
Mivebresib is a potent BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo.
Mivebresib is a potent BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo.
Alternate Name/Synonyms: N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; ABBV-075
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 1445993-26-9
Structure Available?: N/A
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₂₂H₁₉F₂N₃O₄S
Molecular Weight: 459.47
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent BET inhibitor
MDL Number: N/A
PubChem CID: 71600087
SMILES: CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C
InChi: InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6
InChi Key: RDONXGFGWSSFMY-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |